CompletedNCT00102518
Long-term aripiprazole safety in youth with schizophrenia or bipolarity
About this title
Read the official source — NCT00102518Medication studyAges 10–17United States
Understand this study
Who was this study for?
Listed age limits: 10 years to 17 years.
What did participation involve?
The study group receives aripiprazole as a study medication.
- Listed locations
- Birmingham and 49 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateSeptember 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 325
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 10 Years to 17 Years
- Official registry ID
- NCT00102518
- Official title
Show the full official title
A Multi-Center, Open-Label, Safety and Tolerability Study of Flexible-Dose Oral Aripiprazole (2 Mg-30 mg) in the Treatment of Adolescent Patients With Schizophrenia and Child and Adolescent Patients With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham · Little Rock · Costa Mesa
46 more locations
- Fresno
- Orange
- Riverside
- Rosemead
- Sacramento
- Temecula
- Washington D.C.
- Altamonte Springs
- Fort Lauderdale
- Hialeah
- Jacksonville
- Miami
- Orange City
- Tampa
- Atlanta
- Honolulu
- Chicago
- Kansas City
- Lexington
- Louisville
- Lake Charles
- Metairie
- New Orleans
- Somerville
- Clinton
- Saint Charles
- Elmsford
- New York
- Olean
- Rochester
- Chapel Hill
- Cleveland
- Lyndhurst
- Oklahoma City
- Bala-Cynwyd
- Philadelphia
- Memphis
- Bellaire
- DeSoto
- Houston
- San Antonio
- Salt Lake City
- Kirkland
- Seattle
- Spokane
- Wauwatosa
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole.
Who was this study for?
Listed age limits: 10 years to 17 years.
